Stem cell and drug discovery scientists around the world are using our solutions to translate their research into therapies
REPROCELL offers a variety of ready-to-ship products to support Mesenchymal Stem Cell (MSC) research, including iPSC-derived cell lines, media, and other culture reagents. Our cell lines are useful for differentiation and exosome production to promote a variety of disease models for research.
Mesenchymal Stem Cells (MSCs) are involved in a variety of cell therapy and drug discovery programs. REPROCELL can help you drive your next clinical MSC project to success and ensure compliancy with regulatory agencies.
Human Tissue Pharmacology
Human fresh tissue testing bridges the gap between animal studies and clinical trials. We specialize in proof of concept studies in patient-derived living tissues, increasing your clinical success rates and adding commercial value to your preclinical drug assets.
Stem Cell Services for Cell Therapy Manufacturing
GMP iPSC and MSC Master Cell Banks and cells for your cell therapy project. Compliant with regulatory standards of the FDA, EMA, and PDMA.
Alvetex® Bioengineered 3D Tissue Services
Complementing our fresh tissue assays by accurately recreating human biology in bioengineered tissues.
StemEdit Clinical Gene Editing Service
Achieve the genotype you need using CRISPR-SNIPER, before moving on to expensive cell bank manufacturing processes.
Oligonucleotide Synthesis Services
Exceptional quality oligos, delivered worldwide. Custom synthesis, purification, and modification – all based on your requirements.
On the REPROCELL blog
Latest
Pharma AI is Changing Clinical Trials by Optimizing Patient Selection
AI is revolutionizing clinical trials by optimizing patient selection, improving trial outcomes, and accelerating the development of new drugs.
27 November 2024
Key Strategies Central Labs Use to Fast-Track Time to Market
Learn how central labs use automation, outsourcing, and AI to accelerate drug development, reduce costs, and improve clinical trial accuracy and efficiency.
18 November 2024
REPROCELL's Advanced Skin Tissue Engineering
Discover REPROCELL's pioneering 3D skin tissue engineering, enhancing drug development and skincare research with accurate and robust human skin models.
31 October 2024
Plasma or Serum? – You Decide.
Discover the key differences between plasma and serum, their collection methods, and their impact on clinical and experimental outcomes.
17 October 2024
Discover the differentiation potential of induced pluripotent stem cells (iPSC) to cytotoxic NK cells, including recent advancements in research and therapy.
16 October 2024
Corporate News
PRESS RELEASE: New Study Highlights Role of Stromal Support in Bioengineered Human Intestinal Models
New study by Prof Stefan Przyborski at Durham University enhances drug testing models with stromal support in bioengineered human intestinal tissue.
13 November 2024
Press Release: Bioserve India Launches Advanced Stem Cell Products
Discover Bioserve India's advanced stem cell products, supporting innovation in research and drug development.
22 July 2024
REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
30 May 2024
%20vial.jpg)
